KBC Group NV Trims Stock Holdings in Hims & Hers Health, Inc. $HIMS

KBC Group NV decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 41.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,941 shares of the company’s stock after selling 3,487 shares during the period. KBC Group NV’s holdings in Hims & Hers Health were worth $246,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nuveen LLC acquired a new position in shares of Hims & Hers Health during the 1st quarter valued at $58,403,000. CloudAlpha Capital Management Limited Hong Kong acquired a new stake in shares of Hims & Hers Health during the first quarter worth $20,580,000. State of Michigan Retirement System lifted its holdings in shares of Hims & Hers Health by 84.9% during the second quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock valued at $68,748,000 after purchasing an additional 633,300 shares during the last quarter. Jump Financial LLC boosted its position in shares of Hims & Hers Health by 633.2% in the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock valued at $21,437,000 after purchasing an additional 626,496 shares during the period. Finally, Northern Trust Corp increased its stake in Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after purchasing an additional 397,310 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HIMS. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Truist Financial cut their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Finally, Bank of America increased their target price on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $45.27.

Hims & Hers Health Stock Performance

HIMS stock opened at $36.36 on Wednesday. The firm has a 50 day simple moving average of $50.12 and a 200 day simple moving average of $51.42. Hims & Hers Health, Inc. has a 52 week low of $20.02 and a 52 week high of $72.98. The stock has a market cap of $8.28 billion, a P/E ratio of 67.33, a P/E/G ratio of 7.08 and a beta of 2.20. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The firm’s quarterly revenue was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 EPS. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to buy up to 3% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 2,637 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $42.53, for a total transaction of $112,151.61. Following the completion of the sale, the insider directly owned 155,856 shares of the company’s stock, valued at $6,628,555.68. This trade represents a 1.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $57.13, for a total value of $662,250.96. Following the sale, the chief financial officer owned 70,232 shares of the company’s stock, valued at approximately $4,012,354.16. This represents a 14.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 584,209 shares of company stock worth $31,837,916. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.